5 recruiting, 4 active not recruiting, 1 completed, 1 not yet recruiting. 6 Phase 1, 2 Not applicable, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 3, Recruiting 2, Completed 1 |
| Not applicable | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Follicular Lymphoma Grade 3B: new trials by email Literature Review of Follicular Lymphoma Grade 3B trials Research Report on Follicular Lymphoma Grade 3B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment Geriatric-guided supportive care, Conventional supportive care - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B | Not applicable | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 170 | 2026-05-01 | 2026-04-15 |
| Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma C402-CD19-CAR - Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes | Phase 1 | Recruiting | Shanghai Exuma Biotechnology Ltd. | 18 | 2025-03-25 | 2026-09-11 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B | Phase 2 | Active not recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 46 | 2023-11-03 | 2025-02-11 |
| Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy Pell's lentiviral-based gene-edited immune cell therapy - Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma | Recruiting | Pell Bio-Med Technology Co., Ltd. | 49 | 2023-03-31 | 2026-10-09 | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma Mosunetuzumab, DHAX, ICE - Large B-cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 24 | 2023-01-03 | 2026-01-08 |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma CD19-targeted chimeric antigen receptor T-cell - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Pell Bio-Med Technology Co., Ltd. | 49 | 2022-05-31 | 2026-10-09 |
| R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden R-CDOP - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B | Not applicable | Recruiting | oubai, MD/PhD | 64 | 2021-08-30 | 2021-09-16 |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Fludarabine, Cyclophosphamide, CD22 CAR - B-ALL, B-cell Non Hodgkin Lymphoma | Phase 1 | Completed | Matthew Frank | 52 | 2019-09-12 | 2026-03-30 |
| R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B R-CEOP-70, R-CEOP-90, R-CHOP-50 - Diffuse Large B-cell Lymphoma, Follicular Lymphoma Grade 3B | Phase 3 | Unknown | Ruijin Hospital | 648 | 2013-05-01 | 2017-11-14 |
Lymphoma, Large B-Cell, Diffuse (9) · Dendritic Cell Sarcoma, Interdigitating (4) · Lymphoma, B-Cell (3) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (2) · Pyloric Stenosis, Hypertrophic (2) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma, Non-Hodgkin (9) · Lymphoma, B-Cell (8) · Histiocytic Disorders, Malignant (4) · Histiocytosis (4) · Digestive System Diseases (2) · Gastric Outlet Obstruction (2) · Gastrointestinal Diseases (2)
Cyclophosphamide (2) · fludarabine (2) · Ice (1) · relmacabtagene autoleucel (1)
Pell Bio-Med Technology Co., Ltd. (2) · Fondazione Italiana Linfomi - ETS (1) · Matthew Frank (1) · Natera, Inc. (1) · Poseida Therapeutics, Inc. (1) · Ruijin Hospital (1) · Shanghai Exuma Biotechnology Ltd. (1) · Shanghai Ming Ju Biotechnology Co., Ltd. (1) · Verismo Therapeutics (1) · Washington University School of Medicine (1) · oubai, MD/PhD (1)
United States (5) · China (4) · Taiwan (2) · Italy (1)
Chen-Lung Lin, MD (2) · Benedetta Sordi, MD (1) · David Russler-Germain, M.D., Ph.D. (1) · Depei Wu, PhD (1) · Laura A Johnson, PhD (1) · Liang Huang, MD (1) · Matthew Frank, MD, PhD (1) · Simon Heidegger, MD (1) · Weili Zhao, MD, PhD (1) · Weili Zhao, PhD (1)
PMID 28153605, PMID 28478586, PMID 31126528, PMID 31744509, PMID 33107145, PMID 33512414, PMID 35398840, PMID 38996463
K08CA248968 (1)